Andrew R. de Guttadauro
President chez Oncolytics Biotech (U.S.), Inc.
Fortune : 11 037 $ au 31/05/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Kirk Look | M | - |
Oncolytics Biotech (U.S.), Inc.
 Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Oncolytics Biotech (US), Inc. is based in Half Moon Bay, CA. Part of Oncolytics Biotech, Inc., Oncolytics Biotech (US), Inc. is a company that manufactures pharmaceutical products. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Ronald B. Moss | M | 64 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 ans |
| Mary Ann Dillahunty | F | - |
Oncolytics Biotech (U.S.), Inc.
Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Oncolytics Biotech (US), Inc. is based in Half Moon Bay, CA. Part of Oncolytics Biotech, Inc., Oncolytics Biotech (US), Inc. is a company that manufactures pharmaceutical products. | - |
| Richard Kenney | M | 66 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 4 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Andrew R. de Guttadauro
- Réseau Personnel
